A Randomized, Placebo-controlled, Double-blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Adult and Pediatric Patients With Monkeypox Virus Disease
Latest Information Update: 09 Dec 2024
At a glance
- Drugs Tecovirimat (Primary) ; Antivirals
- Indications Monkeypox
- Focus Therapeutic Use
- Acronyms PALM 007
- 05 Dec 2024 Status changed from recruiting to completed.
- 15 Aug 2024 Primary endpoint (Time to lesion resolution)has not been met,as per SIGA Technologies Media Release.
- 15 Aug 2024 Results published in the SIGA Technologies Media Release